Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cogent Biosciences, Inc is a biotechnology business based in the US. Cogent Biosciences shares (COGT) are listed on the NASDAQ and all prices are listed in US Dollars. Cogent Biosciences employs 15 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$6.15 - $14.44|
|50-day moving average||$7.73|
|200-day moving average||$8.74|
|Wall St. target price||$20.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-15,967,000|
|Return on assets TTM||-12.94%|
|Return on equity TTM||-62.23%|
|Market capitalisation||$248.9 million|
TTM: trailing 12 months
There are currently 2.0 million Cogent Biosciences shares held short by investors – that's known as Cogent Biosciences's "short interest". This figure is 33.5% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Cogent Biosciences shares can be evaluated.
Cogent Biosciences's "short interest ratio" (SIR) is the quantity of Cogent Biosciences shares currently shorted divided by the average quantity of Cogent Biosciences shares traded daily (recently around 521427.85145889). Cogent Biosciences's SIR currently stands at 3.77. In other words for every 100,000 Cogent Biosciences shares traded daily on the market, roughly 3770 shares are currently held short.
However Cogent Biosciences's short interest can also be evaluated against the total number of Cogent Biosciences shares, or, against the total number of tradable Cogent Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cogent Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cogent Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0616% of the tradable shares (for every 100,000 tradable Cogent Biosciences shares, roughly 62 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cogent Biosciences.
Find out more about how you can short Cogent Biosciences stock.
We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.
Cogent Biosciences's shares were split on a 1:4 basis on 8 November 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cogent Biosciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cogent Biosciences shares which in turn could have impacted Cogent Biosciences's share price.
Cogent Biosciences, Inc. , a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.